Our partnerships with the pharmaceutical industry
Our partnerships with pharmaceutical companies allow us to deliver vital work supporting people affected by blood cancer.
The support we received in FY24 is detailed below.
Unless otherwise stated, these companies played no part in the organisation, design, or content of any of the work listed.
For more information on how and why we work with the industry, read our Policy on working with pharma.
Our 2024 report
Johnson and Johnson funded £91,290 towards the Blood Cancer Action Plan - a national report to identify and make meaningful and realistic recommendations for change to improve survival of blood cancer patients. Another £180 funded attendance at a CAR-T PAG stakeholder meeting. And finally, £240 funded attendance to a Haematology study day.
£91,290 worth of funding was directed towards the Blood Cancer Action Plan - a national report that will identify and make meaningful, realistic recommendations for change to improve survival of blood cancer patients. A further £9,865 was directed to a translated health information project.
£10,000 went towards a consultancy payment for review of Pfizer’s patient charter. A further £1,200 consultancy payment for Blood Cancer UK's Chief Executive attendance to Pfizer's patient organisation group meetings.
£91,290 worth of funding went towards Blood Cancer Action Plan, a national report to identify and make meaningful and realistic recommendations for change to improve survival of blood cancer patients.
Takeda directed £45,380 worth of funding towards the Blood Cancer Action Plan - a national report that will identify and make meaningful, realistic recommendations for change to improve survival of blood cancer patients.
£466,192 went towards funding for a project to improve awareness and increase recruitment to clinical trials for ethnic minority communities.
Roche provided £25,000 towards the Support Service Transformation project.
£24,543 went towards providing CAR-T information.
£10,000 was directed towards the Health Information Transformation. A further £472.50 funded a Clinical Trials meeting presentation and £135 went towards providing myelodysplastic syndromes (MDS) patient experience insights.
£10,000 was directed towards the Health Information Transformation project.
£3,000 was directed towards the Health Information Transformation project.
£7,500 worth of funding went towards Blood Cancer Action Plan, a national report to identify and make meaningful and realistic recommendations for change to improve survival of blood cancer patients.
£10,000 was directed towards the Health Information Transformation project.
Get in touch with the Corporate Partnerships Team
Get in touch